Ilya Pharma shares latest developments of ILP100-Oral at virtual conference 7th of December showcasing innovations in gut therapeutics
Abstract: "The ILP-technology platform is scalable and enables efficient delivery of immunoregulatory proteins locally on-site – lead program in clinical phase 2 developments"
Most welcome to come work with us on our next big thing, a phase 2b study starting next year. Position filled.